Kommoss, Katharina S. http://orcid.org/0000-0003-2428-2658
Bieler, Tabea
Ringen, Julia
Lehmann, Annika
Mihalceanu, Silvia
Hobohm, Lukas
Keller, Karsten
Brand, Anna
Fischer, Berenice
Kramer, Daniela
Wild, Johannes
Waisman, Ari
Enk, Alexander
Schäkel, Knut
Heikenwälder, Mathias
Karbach, Susanne
Funding for this research was provided by:
Medizinischen Fakultät Heidelberg, Universität Heidelberg (Physician Scientist Programme)
Bundesministerium für Bildung und Forschung
Boehringer Ingelheim Stiftung (Novel, neglected cardiovascular risk factors: molecular mechanisms, therapeutic implications, Novel, neglected cardiovascular risk factors: molecular mechanisms, therapeutic implications)
Deutsche Forschungsgemeinschaft (TRR156/2 246807620, TRR156/2 246807620, TRR156/2 246807620, TRR156/2 246807620, TRR156/2 246807620, TRR355/1 490846870, TRR355/1 490846870, TRR156/2 246807620, TRR1335 360372040)
Peter Hans Hofschneider Foundation
Rainer Hoenig Stiftung
Research Foundation Flanders (30826052)
Helmholtz-Gemeinschaft
Wilhelm Sander-Stiftung (2020.170.1)
Universitätsklinikum Heidelberg
Article History
Received: 4 December 2022
Revised: 4 November 2023
Accepted: 23 November 2023
First Online: 21 December 2023
Declarations
:
: This study was conducted according to the Declaration of Helsinki. The study was approved by the ethics committee of Heidelberg (approval no. S-834/2020), and patients provided written and informed consent. Animal experiments were approved by the Animal Care and Use Committee from Rhineland-Palatine (Landesuntersuchungsamt Rheinland-Pfalz (LUA), Koblenz, approval no. G17-1–076) and Baden-Wuerttemberg (Regierungspräsidium Karlsruhe, Karlsruhe, approval no. G249/20). Guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes were followed.
: Informed consent was obtained from all individual participants included in the study (see ethics approval).
: As no individual person’s data is published (details, images or videos), this does not apply to this study.
: SK declares having received consultancy honoraria from Almiral and lecture honoraria from Janssen-Cilag GmbH. KS discloses that he was an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials of the following companies: AbbVie, Almirall, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Janssen-Cilag GmbH, LEO Pharma, Novartis, Pfizer and UCB. AE discloses speakers’ honoraria/travel grants for Janssen-Cilag GmbH, Abbvie and Eli Lilly. The authors declare that these conflicts are not associated with this work. The other authors have no conflicts of interest to declare.